CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Dilated cardiomyopathy: so many cardiomyopathies! Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Heart Failure and Atrial Fibrillation, Like Fire and Fury Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction

Expert Opinionhttps://academic.oup.com/eurheartj/article-abstract/41/39/3784/5686010?redirectedFrom=fulltext

JOURNAL:Eur Heart J. Article Link

Dilated cardiomyopathy: so many cardiomyopathies!

G Sinagra, PM Elliott, M Merlo et al. Keywords: DCM; LV; HF

ABSTRACT

The current definition of dilated cardiomyopathy (DCM) is relatively simple; namely, a heart muscle disease characterized by left ventricular (LV) or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction.1 In the last decades, the prognosis of patients with DCM has improved significantly with survival free from death and heart transplantation rising to more than 80% at 8-year follow-up.2 This improvement in outcomes reflects the implementation of pharmacological and non-pharmacological therapeutic strategies, earlier diagnosis due to familial and sport-related screening, and individualized long-term follow-up with continuous restratification of risk.